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1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that accounts for most
of dementia cases in elder people. The main features of AD include a progressive deterioration
of intellectual functions, most prominently memory impairment, loss of language ability, and
cognitive deficits. Motor defects appear in the late phases of the disease and basic activities of
daily living are gradually compromised as the pathology progresses to advanced phases, and
are often accompanied by psychosis and agitation [1, 2]. The hallmarks of the disease include
the accumulation of amyloid-β peptide (Aβ) inside neurons and in the extracellular brain
space, and the intracellular formation of neurofibrillary tangles (NFTs) composed of hyper‐
phosphorylated tau protein, loss of synapses at specific brain sites as well as the degeneration
of cholinergic neurons from the basal forebrain [3]. The prevalence of AD is about 8–10 % of
the population over 65 years of age, which increases 2-fold every 5 years afterwards [4, 5]. This
high rate prevalence together with the increase in life expectancy, point to AD as one of the
most serious health concerns wordlwide, whose incidence is expected to tiple in the next 2-3
decades unless more effective therapies are available [6].
The identification of new targets for the development of more effective therapeutic approaches
requires a better understanding of the molecular pathways leading to AD. In this regard, both
genetic and environmental factors are increasingly recognized to contribute to the develop‐
ment of AD, which occurs in two forms. The sporadic form of the disease, which affects people
over 65 years of age and accounts for the vast mayority of AD cases. In a small proportion (6–
8 %), the disease is inherited as an autosomal dominant trait and appears as an early onset in
people younger than 65 years of age. Mutations within three genes, the amyloid precursor
protein (APP) gene on chromosome 21, the presenilin 1 (PSEN1) gene on chromosome 14, and
the presenilin 2 (PSEN2) gene on chromosome 1, have been identified as the main cause of
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
early onset familial AD [7-10]. While these findings are key for our understanding of the
pathogenesis of familial AD, these mutations account for 30–50% of all autosomal dominant
early onset cases.
In the last years, it has become increasingly recognized that cholesterol plays a significant role
in AD. The first evidence of the importance of cholesterol was the discovery that the ε4 allele
of the cholesterol transport protein apolipoprotein E (ApoE) is associated with a higher risk
of developing both familial and sporadic AD and modulates the age of AD onset [11-14].
Despite these findings, the impact and causal role of cholesterol in AD remains controversial
(see below), as exemplified by the inconsistent outcome of statins in modulating AD risk and
progression, which calls for the need for large-scale trials to document whether statins and
cholesterol modification regulate or modify the course of AD [15, 16]. Emerging data, however,
position the small pool of cholesterol in mitochondria as a key player in AD by determining
the susceptibility of neurons to Aβ neuroinflammation, synaptotoxicity and neurotoxicity and
as a culprit of cognitive decline by depleting specific mitochondrial antioxidant defense
mechanisms. In this review, we will briefly summarize the role of cholesterol in AD, focusing
not only in the evidence that cholesterol may foster the amiloidogenic processing of APP and
the generation of Aβ peptide, but most importantly, recent findings indicate that cholesterol
trafficking to mitochondria stands as a novel critical factor that sensitizes to Aβ-induced
neuroinflammation and neurotoxicity, emerging as a potential target for intervention.
2. The involvement of Aβ and cholesterol in AD
2.1. The role of Aβ in AD
Since Aβ was first identified as a component of amyloid plaques, increasing evidence has
suggested that Aβ is a major player in AD pathogenesis. According to the amyloid cascade
hypothesis, the dysregulation of APP metabolism and Aβ deposition are primary events in the
onset of the disease [17, 18]. The Aβ 1–42 and Aβ 1–40 peptides are the major forms found in
amyloid plaques, which are generated by proteolytic cleavage of APP. These plaques are
predominantly found in areas affected by neurodegeneration, such as entorhinal cortex,
amygdala, neocortex, and particularly, hippocampus [19, 20]. While the number of plaques
usually does not correlate with the severity of dementia, clinical correlation between elevated
Aβ deposition in the brain and cognitive decline has been reported [21]. As described below,
several lines of evidence suggest that overproduction and/or reduced clearance of Aβ peptides
are key to amyloid aggregation, which contributes to the development of NFTs and neurode‐
generation in AD pathology. Intraneuronal Aβ can derive by either APP cleavage within
neuronal endocytic compartments, as well as by Aβ internalization from the extracellular
space. Both sources are of relevance in the formation of the pool of Aβ involved in neurode‐
generation. Intraneuronal Aβ accumulation is one of the earliest pathological events in humans
and in animal models of AD, which correlates with early abnormalities in long term potentia‐
tion (LTP), cognitive dysfunctions and precedes the formation of amyloid plaques and NFTs
formation and the neurodegeneration in animal models in which intracellular Aβ and neuronal
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loss have been reported [22-26]. Furthermore, Aβ plaques could generate from the death of
neurons that contained elevated amounts of Aβ and this release can account for the loss of
intraneuronal Aβ immunoreactivity in areas of plaque formation [24, 27, 28]. Moreover, recent
findings indicated that internalized Aβ elicits fibrillization in the multivesicular bodies
(MVBs), which after reaching the plasma membrane, cause cell death and the release of
amyloid structures into the extracellular space, indicating that exosomes derived from MVBs
could release part of the intracellular pool of Aβ to contribute to the extracellular Aβ pool [29,
30]. The contribution of intracellular Aβ to neuronal death has been well documented in
cortical neurons from brains of AD and Down syndrome patients that undergo apoptosis after
accumulation of Aβ42 [31, 32]. In addition, microinjection of Aβ1-42 or cDNA-expressing
cytosolic Aβ1-42 induces cell death in primary human neurons, while neuronal loss associated
with intracellular accumulation of Aβ has been described in a transgenic APP(SL)PS1KI mouse
that closely mimics the development of AD-related neuropathological features of AD [33, 34].
Intracellular Aβ accumulation has been associated with neuritic and synaptic pathology and
transgenic mice harboring constructs that target Aβ intracellularly developed neurodegener‐
ation [35-37]. Furthermore, antibodies against Aβ reduced intraneuronal Aβ accumulation
prevented synaptotoxicity and reversed cognitive impairment in triple transgenic mice [22,
38]. Finally, a coding mutation (A673TT) in APP has been recently shown to protect against
AD and age-related cognitive decline in elderly Icelanders [39]. This mutation that affects the
aspartyl protease β-site in APP significantly reduces the formation of amyloidogenic peptides,
strongly indicating that reducing the β-cleavage of APP protect against the disease. Thus,
although targeting Aβ may be a rationale approach to prevent or treat AD progression, recent
findings have unfolded the diversity of Aβ structures revealed by the immune response to
fibrillar Aβ [40]. This outcome may account for the failure of single therapeutic monoclonal
antibodies against Aβ in the treatment of AD.
2.2. Amiloidogenic processing of APP and Aβ generation
Amiloidogenic processing of APP yields toxic Aβ peptides (Fig 1). In this pathway, the β- and
γ-secretases cleave APP at the N- and C-termini of the Aβ peptide, respectively. APP, β -
secretase, PS1 and Aβ are all present in lipid rafts, which are enriched in cholesterol and
glycosphingolipids. This led to the suggestion that APP in lipid rafts is primarily processed
via the β-secretase, and APP outside of ratfs is processed via the α-secretase pathway. β-
secretase has been characterized as a membrane-bound aspartic protease termed beta-site
APP-cleaving enzyme 1 (BACE1), while γ-secretase is a complex comprised of presenilin-1 or
-2, nicastrin, anterior pharynx-defective 1 (Aph-1) and presenilin enhancer 2 (Pen-2) [41]. β-
arrestin 2, is a novel member of the γ-secretase complex that physically associates with the
Aph-1α subunit of the γ-secretase complex and redistributes the complex toward detergent-
resistant membranes, increasing the catalytic activity of the complex [42]. Moreover, β-arrestin
2 expression is elevated in individuals with AD and its overexpression leads to an increase in
Aβ peptide generation, whereas genetic silencing of Arrb2 (encoding β-arrestin 2) reduces
generation of Aβ in cell cultures and in Arrb2-/- mice. In addition to its amyloidogenic
processing by β- and γ-secretases, APP can be cleaved within the Aβ domain by α-secretase.
This non-amyloidogenic processing prevents the deposition of intact Aβ peptide and results
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in the release of a large soluble ectodomain, sAPPα, from the cell, which has neuroprotective
and memory-enhancing effects. Members of the ADAMs, a disintegrin and metalloprotease
family of proteases, have been shown to possess α-secretase activity [43].
Figure 1. Role of membrane cholesterol in amyloidogenesis. β- and γ-secretases cleave APP at the N- and C-termini of
the Aβ peptide, respectively. APP, β-secretase, PS1 and Aβ are all present in lipid rafts, which are enriched in choles‐
terol and glycosphingolipids. Therefore, APP in lipid rafts is primarily processed via the β-secretase, and APP outside
of ratfs is processed via the α-secretase pathway. In the former, β-secretase-mediated Aβ peptides oligomerize and ac‐
cumulate in plaques contributing to the neurotoxicity of AD.
Besides its extracellular deposition, current evidence indicates the processing and targeting of
APP and Aβ to intracellular sites, including mitochondria [44]. Moreover, levels of mitochon‐
drial APP are higher in affected brain areas and in subjects with advanced disease symptons
[45]. Immunoelectron microscopy analyses indicated the association of APP with mitochon‐
drial protein translocation components, TOM40 and TIM23, which correlated with decreased
import of respiratory chain subunits in vitro, decreased cytochrome oxidase activity, increased
ROS generation and impaired mitochondrial reducing capacity [45].
2.3. The role of cholesterol in AD: facts and controversies
Cholesterol is an essential component of membrane bilayers that regulate strucutral and
functional properties and, hence, a pleiotropic number of cell functions and in the intracellular
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trafficking of proteins [46]. Cholesterol is required for synapse formation, biogenesis of
synaptic vesicles and regulation of neurotransmitter release and the precursor of steroid
hormones and oxysterols, which are critical intermediates in many metabolic pathways
[47-49]. Cholesterol homeostasis is altered in AD; however, whether cholesterol levels are
upregulated or downregulated in AD remains to be established. The pathogenic processing of
APP into toxic Aβ fragments is known to occur in cholesterol-enriched membrane domains of
the plasma membrane, called lipid rafts. The first evidence that cholesterol may impact Aβ
production in the brain came from observations that dietary cholesterol increases amyloid
production in rabbit hippocampal neurons [50]. Work in mice genetically modified to deposit
cerebral Aβ demonstrated that a cholesterol-enriched diet resulted in increased Aβ deposition
and increased amyloid plaque formation [51], and these observations were confirmed in
subsequent studies in mice fed diets enriched in cholesterol [52-55]. As discussed below, very
little cholesterol is transferred from the periphery to the brain due to the impermeability of the
blood brain barrier (BBB), so the observations of diet-induced cholesterol-mediated Aβ
deposition in neurons are puzzling. A potential explanation for these findings is the fact that
BBB permeability is impaired in AD [56, 57]. Exploiting the relative detergent insolubility of
lipid rafts, there has been evidence indicating the localization of APP, the α-, β- and γ-
secretases in rafts [58, 59]. In addition, the activities of BACE1 and γ-secretase are stimulated
by lipid components of rafts, in particular glycosphingolipids and cholesterol. Consistent with
these findings supporting a role for cholesterol in AD pathogenesis, high cholesterol levels
have been shown to correlate with Aβ deposition and the risk of developing AD [60-62].
Patients taking the cholesterol-lowering drug statins have a lower incidence of the disease [62,
63]. Besides ApoE, other genes encoding proteins involved in cholesterol homeostasis,
including cholesteol 24-hydroxylase (CYP46A1), the acyl-coenzyme A:cholesterol acyltrans‐
ferase (ACAT), the cholesterol efflux transporters ABCA1 and ABCA7, and the lipopotrein-
receptor-related protein (LRP) have been linked to the risk, development or progression of AD
[64-68]. Despite this experimental and epidemiological evidence, the role of increased choles‐
terol in AD is controversial with findings showing the opposite. For instance, earlier studies
indicated that hippocampal membranes of AD brains showed a reduced fluidity in the
hydrocarbon core region compared to control subjects that correlated with the cholesterol
content in AD samples [69]. Moreover, reduced cholesterol levels and cholesterol/phospholi‐
pids mole ratio have been reported in the temporal gyrus but unaffected in the cerebellum of
AD patients with respect to controls [70]. Decreased 24-hydroxycholesterol levels that
correlated with lower lathosterol content was reported in the frontal and occipital cortex of
patients with AD compared to subjects controls [71]. In addition, cholesterol levels were
slightly increased in frontal cortex gray matter in AD patients with the ApoE4 genotype
compared with ApoE4 control subjects [72]. Finally, neuronal membrane cholesterol loss has
been shown to enhance Aβ generation in hippocampal membranes from AD patients exhib‐
iting increased colocalization of BACE1 and APP [73], and hippocampal membranes from the
brain of AD patients contain less membrane cholesterol than control [74]. Furthermore, it has
been reported that inhibition of the mevalonate pathway increased production of Aβ and
amyloid plaques [75]. Prospective cohort studies have failed to demonstrate the protective
effect of statins on dementia, while others reports did not replicate the Aβ lowering effect of
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statins in the cerebrospinal fluid [76-81]. In addition to these findings arguing against the
correlation between increased brain cholesterol and AD, there is evidence that both cholesterol
and Aβ reciprocally regulate each other and that Aβ impacts negatively in cholesterol
synthesis, in part, by inhibiting stero-regulated element binding proteins-2 (SREBP-2) cleavage
[82, 83]. Interestingly, the consequent decrease in protein prenylation contributes to Aβ-
induced neuronal death, which is reversed by exogenous supply of isoprenoids. Further work
is needed to ascertain whether the intracelular distribution rather than the levels of brain
cholesterol levels may correlate with disease severity.
3. Regulation of cholesterol metabolism in the brain
3.1. De novo cholesterol synthesis
Compared with other organs, the brain is the highest cholesterol-containing organ, which is
present mainly in unsterified form. Most of the free cholesterol pool is localized predominantly
in specialized membranes (myelin) and to a lesser extent in neurons and glial cells. Experi‐
mental evidence indicates that brain cholesterol is independent of serum cholesterol levels, as
the BBB is impermeable to circulating cholesterol, which determines that both neurons and
glial cells synthesize cholesterol de novo. Oligodendrocytes control the synthesis of myelin and
therefore have the highest capacity to synthesize cholesterol, followed by astrocytes [84, 85].
Cholesterol is synthesized from acetate in a multistep cascade that requires oxygen and energy.
The precursor acetyl-CoA is first converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA)
and then to mevalonate (Fig. 2). The phosphorylation of mevalonate yields 5-pyrophospho‐
mevalonate, which is converted to isopentenyl pyrophosphate (IPP). IPP can be reversibly
transformed to dimethylallyl pyrophosphate (DMAPP), and the combination of both IPP and
DMAPP yields the 10-carbon isoprenoid geranyl pyrophosphate (GPP). The sequential
addition of 1 or 2 more IPP units to GPP generates the 15-carbon and the 20-carbon isoprenoids
farnesyl pyrophosphate (FPP) and the geranylgeranyl pyrophosphate (GGPP), respectively.
FPP branches into the non-sterol pathways, which contributes to the generation of other
derivatives such as ubiquinol, dolichol, and the sterol pathway via conversion into squalene
by squalene synthase, which catalyzes the first committed step in cholesterol synthesis. The
rate-limiting step of cholesterol biosynthesis is the conversion of HMG-CoA to mevalonate
catalyzed by the HMG-CoA reductase (HMGCR), which is bound to endoplasmic reticulum
(ER). Cholesterol levels control HMGCR through several mechanisms. First, high cholesterol
exerts a feedback inhibition by activating HMGCR ubiquitination and subsequent proteasomal
degradation. Moreover, HMGCR expression is regulated by ER-bound transcription factor
SREBP-2, which in turn is controlled by a sterol-sensitive SREBP cleavage-activating protein
(SCAP) [86]. In the presence of sterols, full-length SREBP-2 is restricted to the ER. Upon sterol
depletion, SREBP-2 interacts with SCAP and is transported from the ER to the Golgi apparatus,
where SREBP-2 is cleaved by two proteases and the released N terminus domain acts as a
transcription factor to subsequently enhance the levels of HMGCR [86, 87]. Thus, ER plays a
key role in the supply of endogenous cholesterol synthesis, which operates to meet demand
for cell cholesterol.
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Figure 2. Cholesterol synthesis in the mevalonate pathway. Cholesterol is synthesized from acetate in a multistep cas‐
cade that requires oxygen and energy. The precursor acetyl-CoA is first converted to 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA) and then to mevalonate. This pathway also generates isoprenoids. Farnesyl pyrophosphate (FPP) branches
into the non-sterol pathways, which contributes to the generation of other derivatives such as ubiquinol, dolichol, and the
sterol pathway via conversion into squalene by squalene synthase, which catalyzes the first committed step in cholester‐
ol synthesis. The rate-limiting step of cholesterol biosynthesis is the conversion of HMG-CoA to mevalonate catalyzed by
the HMG-CoA reductase (HMGCR), which is the target of statins. Statins hence will not only block cholesterol synthesis
but also isoprenoids and other non-sterols, which may account for the pleiotropic effects of statins.
3.2. Cholesterol storage and transport
In contrast to developing neurons, which synthesize most of the cholesterol required for
growth and synaptogenesis, mature neurons depend on the availability of exogenous choles‐
terol derived from astrocytes (Figure 3). This process not only ensures steady supply of
cholesterol to neurons but also spares energy, as ATP hydrolysis is required to synthesize
cholesterol de novo [88]. Besides de novo synthesis, astrocytes can also internalize and recycle
the cholesterol released from degenerating nerve terminals and deliver it back to neurons [89].
The transport of cholesterol from astrocytes to neurons requires binding to one of the variants
of ApoE, the most prevalent lipoprotein in the central nervous system. In this process,
cholesterol first forms a complex with ApoE, which is then secreted in a process involving
ABCA1 and ABCG1 transporters [90, 91]. Using cultured cerebellar murine astroglia cells, it
has been shown that partially lipidated apoE, secreted directly by glia, is likely to be the major
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extracellular acceptor of cholesterol released from glia in a process mediated by ABCG1 rather
than ABCA1 [91]. The secreted ApoE–cholesterol complex is then internalized into neurons
predominantly via the LDL receptor (LDLR) as well as LRP, and to a minor extent by very-
low-density lipoprotein receptor (VLDL), ApoE receptor 2, and megalin [92]. The specific
contribution of these receptors in the uptake of ApoE-cholesterol complex and hence in the
maintenance of neuronal cholesterol homeostasis remains to be established. Once internalized
the receptor-bound ApoE–cholesterol complex is delivered to the late endosomes/lysosomes
where acid lipase hydrolyses the cholesterol esters within the lipoprotein complex, resulting
in the release of intracellular free cholesterol. This unesterified cholesterol subsequently exits
the late endosomes/lysosomes via Niemann–Pick type C (NPC) 1 and 2 protein-dependent
mechanism and is distributed primarily to the plasma membrane as well as to the ER, which
serves as a negative feedback sensor for the cholesterol homeostasis genes such as HMGCR
and LDLR. Excess cholesterol, on the other hand, is esterified in the ER by ACAT and stored
in cytoplasmic lipid droplets, which serves as reserve source of cholesterol needed for synaptic
and dendritic formation and remodeling [93, 94].
Figure 3. Cross talk between astrocytes and neurons in cholesterol homeostasis. Although neurons can synthesize cho‐
lesterol de novo in the adult state neurons rely on the delivery of cholesterol from astrocytes, which exhibit a signifi‐
cantly higher rate of de novo cholesterol activity than neurons. Cholesterol packed in ApoE particles assembled in
astrocytes are delivered via ABCA1 carrier to neurons. Excess neuronal cholesterol is transformed into the oxysterol
24S-hydroxysterol (24S-OH) by the CYP46A1 which represents the major mechanism for the elimination of brain cho‐
lesterol, as it crosses the BBB to the periphery for disposal. Oxysterols activate transcription factor LXRβ isoform,
which in turn induces the activation of carriers such as ABCA1 to stimulate trafficking of cholesterol in the form of
ApoE to neurons. 24S-OH inhibits the novo cholesterol synthesis in astrocytes.
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3.3. Cholesterol efflux from the brain
Unlike other organs and epithelial cells, neurons and glial cells do not degrade cholesterol,
therefore in order to maintain homeostasis they export cholesterol to the circulation for its
disposal by peripheral organs. Two different mechanisms are involved in the elimination of
cholesterol from the brain. The major mechanism by which cholesterol is excreted from the
brain is by its conversion to 24S-hydroxylcholesterol—an oxidized lipophilic metabolite that
can freely cross the BBB [95]. The conversion of free cholesterol to 24S-hydroxycholesterol is
mediated by the cytochrome P450-containing enzyme cholesterol 24-hydroxylase, encoded by
the Cyp46A1 gene, which is expressed selectively in the brain [96]. High levels of this enzyme
are found in certain neuronal cells such as pyramidal neurons of the hippocampus and cortex,
Purkinje cells of the cerebellum, thalamic neurons, and in hippocampal and cerebellar
interneurons. Interestingly, a minor fraction of cholesterol 24-hydroxylase immunoreactivity
has also been detected in glial cells from the brains of AD patients [95]. It is estimated that
about 40% of the total cholesterol turnover is mediated by cholesterol 24-hydroxylase [97].
Indeed, deletion of the Cyp46A1 gene encoding cholesterol 24-hydroxylase leads to about 50%
reduction in brain cholesterol excretion. This decrease, however, is compensated by the
reduction in de novo synthesis, thus suggesting a close relationship between synthesis and
metabolism of cholesterol in the brain. The other mechanism of cholesterol elimination, called
reverse cholesterol transport pathway, involves translocation of a fraction of brain cholesterol
to the blood by membrane transport protein such as ABCA1 [98]. The level of ABCA1 is partly
regulated by cholesterol-derived ligand oxysterols (e.g., 24S-hydroxylcholesterol) of the liver
X receptor (LXR), which has been shown to influence the transcription of multiple genes
involved in cholesterol metabolism [99-101]. There are two known LXR isoforms, LXRα and
LHRβ. LXRα expression is mainly limited to the liver, adrenals, intestine and spleen, while
LXRβ is expressed in all tissue types, including the brain. In vivo induction of LXR results in
increased expression of ABCA1 and ABCG1, increased cholesterol efflux and a reduction in
synaptosomal plasma membrane cholesterol [101]. As such, it is expected that LXR agonists
(e.g. T0901317) should lower Aβ levels. However, results with LXR agonists have been
inconsistent. For instance, T0901317 has been shown in some studies to decrease Aβ, while
others reported an increase in Aβ42 without chaning Aβ40 levels [102]. Hence, it is conceivable
that both synthesis and elimination of cholesterol, especially in the adult brain, are not only
tightly regulated but also compartmentalized. Astrocytes are responsible for the majority of
cholesterol synthesis but contribute relatively little to its elimination, whereas neurons with
reduced synthetic ability can eliminate about two thirds of the cholesterol from the brain.
4. Intracellular cholesterol and AD
As a key component of membrane bilayers, intracellular cholesterol traffics to different
compartments to maintain physical and functional membrane properties. Cholesterol that
enters the cell via the endocytic pathway is transported to the ER for processing, while
cholesterol synthesized in the ER de novo it is transported to the plasma membrane within a
short time frame. Of relevance to AD pathogenesis, in the following sections we will focus on
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the endo-lysosomal cholesterol and in the small pool of cholesterol in mitochondria and their
contribution to AD.
4.1. Endo-lysosomal cholesterol
The supply of cholesterol from astrocytes to neurons via receptor-bound ApoE-cholesterol
complex relies on the trafficking and subsequent hydrolysis of these complexes in endo/
lysosomes. The generated free cholesterol exits lysosomes via NPC1/2 proteins to be distrib‐
uted to other membrane bilayers. The impact of NPC proteins in intracelular cholesterol
homeostasis has been best characterized in the NPC disease, a neurological disorders caused
by mutations in NPC1/2 proteins characterized by increased accumulation of cholesterol and
other lipids (e.g. glycosphingolipids) in lysosomes in the affected organs, predominantly brain
and liver. NPC knockout mice, which mimic the pathology of NPC patients, exhibit increased
lysosomal cholesterol in cerebellum, mainly in Purkinje cells, and suffer from progressive
motor deterioration and a short life span (typically 8-10 weeks). NPC disease and AD share
many parallels including endo/lysosomal abnormalities and APP processing and Aβ accu‐
mulation. Previous findings have shown that mutated NPC1 in mice causes the accumulation
of Aβ40 and Aβ42, which coincided with accumulation of presenilins in early endocytic
compartment [103]. Similar findings have been reported in human NPC1 brain, with accumu‐
lation of Aβ ocurring in early endosomes [104]. In CHO cells deficient in NPC1 protein and in
cells treated with U18666A, which inhibits NPC1/2, Aβ and presenilin accumulation were
found in late endosomes [105]. However, the expression of NPC1 in AD has been poorly
characterized. Quite intriguingly, recent findings have reported increased expression of the
lysosomal cholesterol transporter NPC1 in AD [106]. NPC1 expression was described to be
upregulated at both mRNA and protein levels in the hippocampus and frontal cortex of AD
patients compared to controls subjects. However, no difference in NPC1 expression was
detected in the cerebellum, a brain region that is relatively spared in AD. Moreover, murine
NPC1 mRNA levels increased in the hippocampus of 12-month-old APP/PS1 mice compared
to wild type mice. While these findings strongly suggest the lack of lysosomal cholesterol
accumulation in AD, endosomal abnormalities have been found in AD that precede amyloid
and tau pathology in the neocortex. In addition to the proteolytic processing by secretases,
APP and its corresponding C-terminal fragments are also metabolized by lysosomal proteases.
SORLA/SORL1 is a unique neuronal sorting receptor for APP that has been causally implicated
in sporadic and autosomal dominant familial AD. Brain concentrations of SORLA are inversely
correlated with Aβ in mouse models and AD patients. Indeed, transgenic mice overexpressing
SORLA exhibit decreased Aβ concentrations in brain [107]. Mechanistically, Aβ binds to the
amino-terminal VP10P domain of SORLA and this binding is impaired by a familial AD
mutation in SORL1. Although previous studies have shown that lysosomal cholesterol
accumulation impairs autophagy by disrupting lysosomal function [108], the lysosomal
impairment and subsequent contribution to decreased Aβ degradation in AD may occur
through mechanisms independent of cholesterol accumulation in lysosomes. Moreover,
sphingosine-1-phosphate (S1P) accumulation by S1P lyase deficiency has recently been shown
to impair lysosomal APP metabolism, resulting in increased Aβ accumulation [109]. The
intracellular accumulation of S1P interferes with the maturation of cathepsin D and degrada‐
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tion of Lamp2, suggesting a general impairment of lysosomal function and autophagy.
Sphingolipids have strong affinity to bind cholesterol and play a role in Alzheimer disease
[110]. However, it remains to be established whether increased lysosomal cholesterol may
contribute to impaired lysosomal Aβ degradation and if sphingolipids accumulate in lyso‐
somes in AD.
4.2. Mitochondrial cholesterol
Unlike plasma membrane, mitochondria are cholesterol-poor organelles. The limited pool of
mitochondrial cholesterol plays important physiological roles, such as in the synthesis of
steroids in specialized tissues and bile acids in the liver. However, under pathological
conditions the unphysiological accumulation of cholesterol in mitochondrial membranes have
profound effects in mitochondrial function and antioxidant defense and has emerged as an
important factor in liver diseases and neurodegeneration [111-114]. In particular, the transport
of cholesterol from the outer to the inner mitochondria is essential for the generation of steroid
precursor pregnenolone upon metabolism of cholesterol by the P540 side-chain cleavage
enzyme CYP11A1. Availability of cholesterol in mitochondria inner membrane is rate-limiting
step in steroidogenesis and is a highly regulated process.
StARD1 is the founding member of a family of lipid transporting proteins that contain StAR-
related lipid transfer (START) domains. StARD1 is an outer mitochondrial membrane protein
which was first described and best characterized in steroidogenic cells where it plays an
essential role in cholesterol transfer to the mitochondrial inner membrane for metabolism by
CYP11A1 to generate pregnenolone. Despite similar features with StARD1, other START
members cannot replace StARD1 deficiency as global StARD1 knockout mice dye within 10
days due to adrenocortical lipoid hyperplasia [115]. These findings imply that other members
of the family cannot functionally replace StARD1, indicating the key role of this member in
the regulation of cholesterol trafficking to the mitochondrial inner membrane. Recent findings
in APP/PS1 models of AD have indicated the expression of StARD1 in neurons, which correlate
with the age-dependent increase in mitochondrial cholesterol [114, 116]. Consistent with these
findings in experimental models, enhanced immunocytochemical localization of StARD1 has
been described in the pyramidal hippocampal neurons of AD-affected patients [117]. Given
the role of StARD1 in the mitochondrial transport of cholesterol and hence in the modulation
of mitochondrial cholesterol levels, the increased expression of StARD1 in AD patients, would
strongly suggest that mitochondrial cholesterol accumulation may actually occur in patients
with AD. Furthermore, the increase in mitochondrial cholesterol in brain mitochondria of
Alzheimer’s disease was not accompanied by a selective increase in mitochondrial-associated
membranes (MAM), a specific membrane domain made of ER and mitochondria bilayers
thought to be of relevance in the traffic of lipids, suggesting that StARD1-mediated cholesterol
trafficking to mitochondria is independent of MAM. TSPO, a protein particularly abundant in
steroidogenic tissues and primarily localized in the mitochondrial outer membrane, has been
suggested to play an important role in steroidogenesis via the transport of cholesterol to the
mitochondrial inner membrane (IMM) [118, 119]. However, quite interestingly, recent studies
using tissue-specific genetic deletion of TSPO demonstrated that TSPO is dispensable for
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steroidogenesis in Leydig cells [120], questioning the relevance of previous findings on TSPO
using pharmacological ligands and inhibitors. These data underscore that TSPO does not play
a significant role in the trafficking of cholesterol to IMM, and highlights the relevance of
StARD1 in this process. Overall, these findings underscore the accumulation of cholesterol in
mitochondrial membranes in patients and models of AD, and quite interestingly, paralell the
increase in mitochondrial cholesterol observed in brain and liver mitochondria in NPC,
arguing that this pool of cholesterol may be a common nexus in both AD and NPC.
5. Mitochondrial cholesterol promotes AD by depleting GSH
In addition to the amyloidogenic effect of cholesterol by fostering Aβ generation from APP,
recent data has provided evidence that mitochondrial cholesterol accumulation sensitizes
neurons to Aβ-induced neuroinflammation and neurotoxicity by depleting mGSH, effects that
are prevented by mGSH replenishment [114, 116]. The mechanism of mitochondrial cholesterol
accumulation involves the upregulation of StARD1 induced by Aβ via ER stress, confirming
previous findings in hepatocytes [121]. Consistent wiht the reported increased expression of
StARD1 in pyramidal hippocampal neurons of AD-affected patients, it is likely that this
outcome may be accompanied by increased accumulation of cholesterol in mitochondria and
subsequent depeltion of mGSH levels [117]. Moreover, a novel mouse model engineered to
have enhanced cholesterol synthesis by SREBP-2 overexpression superimposed to APP/PS1
mutations triggered Aβ accumulation and tau pathology [122]. This triple transgenic model
exhibited increased mitochondrial cholesterol loading and mGSH depletion and accelerated
Aβ generation by β-secretase activation compared to APP/PS1 mice. Moreover, SREBP-2/APP/
PS1 mice displayed synaptotoxicity, cognitive decline, tau hyperphosphorylation and neuro‐
fibrillary tangle formation in the absence of mutated tau, indicating that cholesterol, particu‐
larly mitochondrial cholesterol, can precipitate Aβ accumulation and tau pathology.
Importantly, in vivo replenishment of mGSH with cell-permeable GSH monoethyl ester (GSH-
EE) attenuated neuropathological features of AD in SREBP-2/APP/PS1 mice. These findings
established that mitochondrial cholesterol promotes AD by selective depletion of mGSH
stores. Therefore, understanding the molecular mechanisms on this cause-and-effect relation‐
ship may be of interest in AD.
The properties of GSH transport in isolated rat brain mitochondria appear to differ from those
reported previously other tissues such as liver and kidney, as they were influenced most by
inhibitors of the tricarboxylate carrier, citrate, isocitrate, and benzenyl-1,2,3-tricarboxylate
[123] Moreover, in mouse brain mitochondria it has been shown that 2-oxoglutarate (OGC)
and dicarboxylate (DIC) are both expressed in cortical neurons and astrocytes [124]. In
addition, butylmalonate, an inhibitor of DIC, significantly decreased mGSH, suggesting DIC
as an important GSH transporter in mouse cerebral cortical mitochondria. Interestingly, a role
for UCP2 in the transport of mGSH has been described in neurons, suggesting that the
transport of protons back into the matrix by UCP2 may favor the movement of GSH [125].
These studies suggest that multiple IMM anion transporters might be involved in mGSH
transport and that they might differ in different cell populations within the brain. However,
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the fact that mitochondrial cholesterol loading selectively depleted mGSH indicated that this
transport function is sensitive to cholesterol-mediated changes in membrane dynamics, similar
to what has been reported in liver mitochondria. Indeed, the effect of cholesterol in the
regulation of mGSH is mediated by the susceptibility of the OGC to perturbations in membrane
dynamics. Functional expression analyses in Xenopus laevis oocytes microinjected with OGC
cRNA showed enhanced transport of GSH in isolated mitochondria [126]. Moreover, choles‐
terol enrichment impairs the transport kinetics of 2-oxoglutarate via the OGC by decreasing
mitochondrial membrane fluidity. Restoration of membrane dynamics by the fatty acid analog
A2C improves the activity of OGC and mGSH transport despite cholesterol enrichment.
Therefore, strategies aimed to replenish mitochondrial membrane physical properties may be
of relevance to AD by replenishing mGSH.
6. Regulation of mitochondrial cholesterol
The ER plays an essential role in the integration of multiple metabolic signals and the main‐
tenance of cell homeostasis, particularly protein synthesis and folding. Under stress conditions
induced by protein misfolding, the ER triggers an adaptive response called uncoupled protein
response (UPR). To resolve ER stress, UPR promotes a decrease in protein synthesis, and an
increase in protein degradation and chaperone production for protein folding. Aβ is well
known to induce ER stress, which is believed to mediate in part the pathogenesis of AD [127].
Moreover, tauroursodeoxycholic acid (TUDCA), a chemical chaperone that prevents ER stress,
has been shown to restore the mGSH pool in alcohol fed rats [128] and ameliorates alcohol-
induced ER stress [121]. In line with these findings in liver, we have recently reported that
TUDCA and PBA abolish Aβ-induced hepatic ER stress, mitochondrial cholesterol loading
and subsequent mGSH depletion [116]. Emerging evidence has demonstrated that StARD1 is
a previously unrecognized target of the UPR and ER stress signaling. Indeed, tunicamycin, an
ER stress trigger, induces the expression of StARD1 in isolated hepatocytes and this effect is
prevented by TUDCA treatment [121]. Moreover, mice fed a high cholesterol diet (HC)
exhibited increased expression of StARD1. However, HC feeding downregulates the expres‐
sion of SREBP-2-regulated target genes, including hydroxymethylglutaryl Co-A reductase,
demonstrating that StARD1 is and an ER stress but not SREBP-2 regulated gene. In contrast to
StARD1, the role of ER stress in the regulation of StART family members has been limited to
StARD5 [129, 130], with conflicting results reported for StARD4 [130, 131]. As the UPR
comprises three transducers, namely inositol requiring (IRE) 1α, PKR-like ER kinase (PERK),
and activating transcription factor (ATF) 6α, which are controlled by the master regulator
glucose-regulated protein 78 (GRP78 also known as BiP), further work is needed to examine
the relative contribution of the involved arms of the UPR in the regulation of StARD1 by Aβ.
Besides ER stress, StARD1 activation is regulated at the transcriptional and post-translational
levels. In murine steroidogenic cells StARD1 activity and subsequent steroidogenesis increases
upon StARD1 phosphorylation at serine residues [132, 133]. Whether or not StARD1 phos‐
phorylation by Aβ regulates mitochondrial cholesterol homeostasis remains to be explored. If
so, then the identification of putative kinases that phosphorylate and activate StARD1 may be
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of potential relevance in AD. The other unresolved question relates as to the mechanism
whereby Aβ induces ER stress. As ER Ca2+ homeostasis is a key housekeeping mechanism to
maintain ER function, it is conceivable that Aβ may disrupt ER Ca2+, thereby causing ER stress.
Whether Aβ modulates the activity of the ER Ca2+ pump SERCA, whose disruption is known
to trigger ER stress remains to be investigated.
7. Concluding remarks
With an expected increase in cases, AD may represent one of the most important health
burdens in the near future worlwide. Therefore the identification of effective therapeutic
treatments for AD is of priority for health authorities around the world. Unfortunately our
limited understanding of the molecular pathways underlying AD has curved the possibilities
to have effective treatments at hand. While cholesterol and in particular hypercholesterolemia
has been identified as a risk factor for AD development, the causal effect of cholesterol and the
impact of cholesterol-lowering approach in AD still remains controversial. Unexpectedly,
evidence in the last five years has indicated that the small pool of cholesterol in mitochondria
plays an important role in AD, as its accumulation in mitochondria causes mGSH depletion
amplifying the neurotoxic effects of Aβ peptides. Therefore, targeting mGSH may be of
therapeutic relevance in AD. However, mGSH is regulated by its transport through mito‐
chondrial inner membrane via specific carriers that are sensitive to changes in mitochondrial
membrane properties. Hence the mere increase in cytosolic GSH by GSH prodrugs, such as
N-acetylcysteine, may not be effective in restoring mGSH as cytosolic GSH would not be
transported into mitochndrial matrix due to cholesterol-mediated disruption in mitochondrial
membrane dynamics. Thus, more specific approaches would imply the use of membrane-
permeable GSH prodrugs such as GSH ethyl ester, which has been shown to protect against
AD in experimental models and is known to cross the BBB. Alternatively, targeting the increase
in mitochondrial cholesterol by antagonizing StARD1 may arise as another attractive possiblity
in the future. This approach requires a better understanding of the cell biology of StARD1 and
in the identification of BBB permeable specific StARD1inhibitors. We are looking forward to
these and other more exciting discoveries to start controlling the onset and progression of this
devastating disease.
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